Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck, GE Healthcare in AD Imaging Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Merck, GE Healthcare in AD Imaging Agreement

PET imaging agent to support MK-8931 development

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck and GE Healthcare have entered a collaboration, license and supply agreement for use of [18F]Flutemetamol, an investigational PET imaging agent, to support Merck’s development of MK-8931, an oral beta amyloid precursor protein inhibitor for Alzheimer’s disease (AD).
 
GE Healthcare will supply [18F]Flutemetamol for clinical trials and evaluate this investigational agent as a companion diagnostic tool. A joint Merck and GE Healthcare Imaging Advisory Committee will oversee the studies.
 
“There is a serious unmet need for a reliable method for measuring beta amyloid deposits to help physicians diagnose Alzheimer’s disease at its different stages and study its progression,” said Darryle Schoepp, Ph.D., senior vice president, head of neuroscience and ophthalmology, Merck Research Laboratories. “This agreement will allow us to employ an investigational imaging agent to help identify patients who might benefit from an anti-amyloid therapy and enable clinical evaluation of our lead BACE inhibitor candidate for Alzheimer’s disease, MK-8931.”
 
“In clinical trials, [18F]Flutemetamol demonstrated consistent performance in the visual detection of beta amyloid in the brain when compared with histopathology data,” said Jonathan Allis, general manager, PET, GE Healthcare Medical Diagnostics. “[18F]Flutemetamol imaging has the potential to be part of a larger diagnostic workup that may help doctors rule out Alzheimer’s disease by reliably showing the absence of amyloid deposits in patients with unexplained loss of cognitive function.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics